These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10382869)

  • 61. Future of the quinolones.
    Ball P
    Semin Respir Infect; 2001 Sep; 16(3):215-24. PubMed ID: 11562902
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Structural features of new quinolones and relationship to antibacterial activity against Gram-positive bacteria.
    Emami S; Shafiee A; Foroumadi A
    Mini Rev Med Chem; 2006 Apr; 6(4):375-86. PubMed ID: 16613574
    [TBL] [Abstract][Full Text] [Related]  

  • 63. In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria.
    López Y; Tato M; Espinal P; Garcia-Alonso F; Gargallo-Viola D; Cantón R; Vila J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6389-92. PubMed ID: 24080666
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae.
    Vera-Cabrera L; Ochoa-Felix EY; Gonzalez G; Tijerina R; Choi SH; Welsh O
    Antimicrob Agents Chemother; 2004 Mar; 48(3):1037-9. PubMed ID: 14982804
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Therapeutic advances of new fluoroquinolones.
    Ball P; Fernald A; Tillotson G
    Expert Opin Investig Drugs; 1998 May; 7(5):761-83. PubMed ID: 15991967
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Potent non-6-fluoro-substituted quinolone antibacterials: synthesis and biological activity.
    Ledoussal B; Bouzard D; Coroneos E
    J Med Chem; 1992 Jan; 35(1):198-200. PubMed ID: 1732530
    [No Abstract]   [Full Text] [Related]  

  • 67. Crystal structure and characterization of the bismuth(III) compound with quinolone family member (ciprofloxacin). Antibacterial study.
    Turel I; Leban I; Bukovec N
    J Inorg Biochem; 1997 Jun; 66(4):241-5. PubMed ID: 9161011
    [TBL] [Abstract][Full Text] [Related]  

  • 68. ANTIMICROBIAL PROPERTIES OF NATIVE ULSTER MACROFUNGI (MUSHROOMS AND TOADSTOOLS) TO CLINICAL PATHOGENS.
    Nelson D; Moore JE; Millar BC; Rao JR
    Ulster Med J; 2019 May; 88(2):130-132. PubMed ID: 31105354
    [No Abstract]   [Full Text] [Related]  

  • 69. Evaluation of two in vitro pharmacodynamic simulation models: microfiltration versus centrifugation-filtration.
    Alou L; Sevillano D; Bugella JH; Fuentes F; Gómez-Lus ML; Prieto J
    Int J Antimicrob Agents; 2001 May; 17(5):365-70. PubMed ID: 11337222
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The role of quinolones in chronic obstructive pulmonary disease.
    Banerjee D; Honeybourne D
    Curr Opin Infect Dis; 1999 Dec; 12(6):543-7. PubMed ID: 17035819
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.
    Gozalbes R; Brun-Pascaud M; Garcia-Domenech R; Galvez J; Girard PM; Doucet JP; Derouin F
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2771-6. PubMed ID: 10991859
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quinolone antibiotics.
    Pham TDM; Ziora ZM; Blaskovich MAT
    Medchemcomm; 2019 Oct; 10(10):1719-1739. PubMed ID: 31803393
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Grepafloxacin: microbiological properties.
    Marriott MS
    Clin Microbiol Infect; 1998 Mar; 4 Suppl 1():S9-S14. PubMed ID: 11869244
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [CHARACTERISTICS OF LEVOFLOXACIN AND ITS CLINICAL APPLICATION (REVIEW)].
    Shtaniuk E; Kovalenko T; Krasnikova L; Mishyna M; Vovk O
    Georgian Med News; 2020 Oct; (307):173-180. PubMed ID: 33270600
    [TBL] [Abstract][Full Text] [Related]  

  • 75. New fluoroquinolones: a class of potent antibiotics.
    De Souza MV
    Mini Rev Med Chem; 2005 Nov; 5(11):1009-17. PubMed ID: 16307530
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.
    Poole K
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2233-41. PubMed ID: 10952561
    [No Abstract]   [Full Text] [Related]  

  • 77. Bowel microorganisms--a target for selective antimicrobial control.
    van Saene HK; Percival A
    J Hosp Infect; 1991 Sep; 19 Suppl C():19-41. PubMed ID: 1684194
    [TBL] [Abstract][Full Text] [Related]  

  • 78. SMI's 2nd Annual Superbugs and Superdrugs Conference: innovations in anti-infectives.
    Barrett JF
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1665-72. PubMed ID: 11203453
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Structure of grepafloxacin relative to activity and safety profile.
    Hooper DC
    Clin Microbiol Infect; 1998 Mar; 4 Suppl 1():S15-S20. PubMed ID: 11869245
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Microbial transformations of antimicrobial quinolones and related drugs.
    Parshikov IA; Sutherland JB
    J Ind Microbiol Biotechnol; 2012 Dec; 39(12):1731-40. PubMed ID: 23007957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.